The NMC Health share price is down 50% this week. Is the company on life-support or should you buy?

A research report casting doubt on accounting practices at NMC (LSE: NMC) has destroyed its share price, but are things as bad as they seem?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Things have taken a turn for the worse for shareholders in NMC Health (LSE: NMC) this week. The share price has tumbled from 2,585p on Monday to about 1,250p at the time of writing. NMC was previously well-liked, but now it is firmly out of favour.

The cause was a Muddy Waters research report that said it had “serious doubts about the company’s financial statements, including its asset values, cash balance, reported profits, and reported debt levels“. 

At the same time, Muddy also announced that it was taking a short position against NMC shares. That position benefits from a decline in the NMC share price, and Muddy got what it wanted.

NMC has now responded to the claims. Has Muddy made a misdiagnosis? I don’t think so.

Bad medicine

NMC valued its assets at $3.47b at the end of June 2019. Goodwill accounts for $1.44b of those assets. This goodwill asset came from acquisitions and represents the premium NMC paid above the estimated market value of the acquired assets.

If NMC grossly overpaid for its acquisitions, which Muddy suggests it did, then 41% of the assets are liable to substantial write-downs in the future. That is worrying, even if, as the company has said in response to Muddy’s report, that it valued its acquisitions fairly and had third-party valuations done as well.

Fighting back

NMC has said that when its suppliers get paid by a financier, who is later reimbursed by NMC at the original invoice amount, that amount is recognised in trade payables as it should be. Muddy Waters claims these invoices are an off-balance sheet source of financing. Since NMC has not broken down its trade payables, I cannot say much more.

Muddy Waters believes NMC has inflated its cash and equivalents balances because they attract negligible interest. I took the average of the opening and closing balances for the first six months of this year, which, with the half-year finance income number, means NMC gets about 1.9% interest annually on its cash balances.

That’s not far away from the 2% NMC claims you get on cash deposits in the Middle East. The rate makes sense if NMC needs most of its cash to support working capital and therefore places it in short-term, deposit-like accounts, as it claims it does.

Diagnosis

If the bulk of those cash balances are needed to support working capital, then announcing a $200m share buyback seems potentially ruinous.

Sure, the NMC share price was in freefall, and its management probably thought a buyback announcement might shore it up. However, the buyback consumes nearly 50% of NMC’s cash and equivalents if carried out in full, which means it can’t be done in full without taking on additional debt.

Furthermore, on Tuesday NMC announced it wanted to buy back $90m of convertible bonds issued just last year. Is that going to eat into working capital cash, or is more debt going to be issued? At the very least, it means that NMC management appears to have issued $90m of debt needlessly.

NMC has not convinced me that the allegations made by Muddy Waters are baseless. There are inconsistencies in the company’s defence. The 39-page report issued by Muddy Waters is available for download and it raises many more issues than I have been able to cover here. I will avoid this stock.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »